-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the last wave of transformation and innovation of traditional pharmaceutical companies, PD-1/PD-L1 monoclonal antibodies and biosimilar drugs have become the footholds of various pharmaceutical companies
.
According to the industry, the pace of innovation will never stall.
In the new round of pharmaceutical innovation, ADC (antibody-conjugated drugs) has become the focus of many pharmaceutical companies
.
In recent years, with continuous breakthroughs in key technologies, the development of ADC drugs has climaxed.
In addition to the multinational pharmaceutical giants laying out the ADC track, domestic pharmaceutical companies and capital are also vying to enter ADC drugs.
License in/out transactions are frequently occurring, and R&D enthusiasm Soaring
.
For example, Zhenbaodao Pharmaceutical said that after the company determined the ADC track, it visited dozens of ADC R&D companies across the country from 2019 to 2020
.
In June 2021, Zhenbaodao Pharmaceutical announced that it would invest 400 million yuan in Terris to enter the field of biological medicine
.
This financing event not only represents Zhenbaodao’s official entry into the biopharmaceutical field, but also announces the return of Terris Pharmaceuticals to the ADC competition track
.
"Teruisi's ability in production is crucial to our ADC layout
.
Teruisi's existing production capacity can ensure the supply of drugs for clinical research in the early stages of our ADC deployment
.
" said the relevant person
.
In 2021, in addition to investing in Terris, Zhenbaodao Pharmaceuticals has successively invested in many ADC R&D companies such as Duxi Biology and Ecoris.
At the same time, Zhenbaodao also invested 1.
7 billion yuan in the development of anti-tumor ADC drugs.
The Hangzhou Biopharmaceutical Project has gradually systematized the layout of ADC drugs
.
It is understood that in recent years, domestic pharmaceutical companies such as Genting Xinyao, Qilu Pharmaceutical, Lepu Bio, Xinda Bio, etc.
have competed to deploy ADC drug pipelines through License in (authorized introduction) and quickly seized the track
.
Among them, in August of this year, Rongchang Biotech's vedcitusimab set a new record for China's single-drug overseas license out transaction with US$2.
6 billion, which made its peers salivate, and the domestic ADC drug research and development enthusiasm was once again ignited
.
And Hengrui Medicine will begin to introduce pipelines in 2021.
.
Within one year, Hengrui Pharmaceuticals and Yingli Pharmaceuticals, Wanchun Pharmaceuticals, Tianguangshi, and CStone Pharmaceuticals reached a cooperation with four innovative pharmaceutical companies, and added three phase III clinical phase drugs to their pipelines.
And a CTLA-4 monoclonal antibody
.
ADC has been the key layout of Hengrui Medicine since 2020, and has declared 3 new ADC drugs in 2021
.
Among them, according to the news from the CDE website on October 25, Hengrui Medicine's ADC drug SHR-A1921 was approved for clinical use, and its indication is the treatment of patients with advanced malignant solid tumors
.
It is reported that, currently, Hengrui Medicine has 7 ADC projects, 5 of which have started clinical trials
.
In addition, on the morning of December 1, 2021, Huadong Medicine announced that the US key single-arm clinical trial (SORAYA trial) of the new ADC drug IMGN853 (MirvetuximabSoravtansine) developed in cooperation with ImmunoGen, Inc.
has reached the primary research endpoint.
The confirmed objective remission rate was 32.
4%, the median duration of remission was 5.
9 months, and 5 cases had complete remission.
The clinical trial results showed that it was well tolerated
.
Regarding the layout of ADC drugs, Huadong Medicine said that in the future, the company will continue to increase its layout in the ADC anti-tumor field.
Based on unmet clinical needs, it will continue to develop ADC products for different cancers, relying on the company's existing biotechnology research and development platform.
And cooperate with domestic and international R&D companies that focus on the research and development of ADC drug innovation products, such as Nuolin Biology and ImmunoGen, to strengthen and deepen the product innovation chain and the ADC field ecological chain
.
It is understood, ADC drugs broad indications, has been expanded by the blood to the tumor solid tumors, covering leukemia, lymphoma, breast cancer, myeloma, head and neck cancer, and gastric cancer
.
Data show that, as of now, a total of 14 ADC drugs have been approved for marketing worldwide
.
In recent years, many domestic pharmaceutical companies are also competing to enter the ADC track, including traditional old-brand pharmaceutical companies, such as Hengrui Pharmaceuticals, Kelun Pharmaceuticals, Qilu Pharmaceuticals, CSPC, etc.
; Biotech, such as BeiGene, Junshi Biology, Genting Xinyao, etc.
, the ADC drug market has entered the stage of competition
.
.
According to the industry, the pace of innovation will never stall.
In the new round of pharmaceutical innovation, ADC (antibody-conjugated drugs) has become the focus of many pharmaceutical companies
.
In recent years, with continuous breakthroughs in key technologies, the development of ADC drugs has climaxed.
In addition to the multinational pharmaceutical giants laying out the ADC track, domestic pharmaceutical companies and capital are also vying to enter ADC drugs.
License in/out transactions are frequently occurring, and R&D enthusiasm Soaring
.
For example, Zhenbaodao Pharmaceutical said that after the company determined the ADC track, it visited dozens of ADC R&D companies across the country from 2019 to 2020
.
In June 2021, Zhenbaodao Pharmaceutical announced that it would invest 400 million yuan in Terris to enter the field of biological medicine
.
This financing event not only represents Zhenbaodao’s official entry into the biopharmaceutical field, but also announces the return of Terris Pharmaceuticals to the ADC competition track
.
"Teruisi's ability in production is crucial to our ADC layout
.
Teruisi's existing production capacity can ensure the supply of drugs for clinical research in the early stages of our ADC deployment
.
" said the relevant person
.
In 2021, in addition to investing in Terris, Zhenbaodao Pharmaceuticals has successively invested in many ADC R&D companies such as Duxi Biology and Ecoris.
At the same time, Zhenbaodao also invested 1.
7 billion yuan in the development of anti-tumor ADC drugs.
The Hangzhou Biopharmaceutical Project has gradually systematized the layout of ADC drugs
.
It is understood that in recent years, domestic pharmaceutical companies such as Genting Xinyao, Qilu Pharmaceutical, Lepu Bio, Xinda Bio, etc.
have competed to deploy ADC drug pipelines through License in (authorized introduction) and quickly seized the track
.
Among them, in August of this year, Rongchang Biotech's vedcitusimab set a new record for China's single-drug overseas license out transaction with US$2.
6 billion, which made its peers salivate, and the domestic ADC drug research and development enthusiasm was once again ignited
.
And Hengrui Medicine will begin to introduce pipelines in 2021.
.
Within one year, Hengrui Pharmaceuticals and Yingli Pharmaceuticals, Wanchun Pharmaceuticals, Tianguangshi, and CStone Pharmaceuticals reached a cooperation with four innovative pharmaceutical companies, and added three phase III clinical phase drugs to their pipelines.
And a CTLA-4 monoclonal antibody
.
ADC has been the key layout of Hengrui Medicine since 2020, and has declared 3 new ADC drugs in 2021
.
Among them, according to the news from the CDE website on October 25, Hengrui Medicine's ADC drug SHR-A1921 was approved for clinical use, and its indication is the treatment of patients with advanced malignant solid tumors
.
It is reported that, currently, Hengrui Medicine has 7 ADC projects, 5 of which have started clinical trials
.
In addition, on the morning of December 1, 2021, Huadong Medicine announced that the US key single-arm clinical trial (SORAYA trial) of the new ADC drug IMGN853 (MirvetuximabSoravtansine) developed in cooperation with ImmunoGen, Inc.
has reached the primary research endpoint.
The confirmed objective remission rate was 32.
4%, the median duration of remission was 5.
9 months, and 5 cases had complete remission.
The clinical trial results showed that it was well tolerated
.
Regarding the layout of ADC drugs, Huadong Medicine said that in the future, the company will continue to increase its layout in the ADC anti-tumor field.
Based on unmet clinical needs, it will continue to develop ADC products for different cancers, relying on the company's existing biotechnology research and development platform.
And cooperate with domestic and international R&D companies that focus on the research and development of ADC drug innovation products, such as Nuolin Biology and ImmunoGen, to strengthen and deepen the product innovation chain and the ADC field ecological chain
.
It is understood, ADC drugs broad indications, has been expanded by the blood to the tumor solid tumors, covering leukemia, lymphoma, breast cancer, myeloma, head and neck cancer, and gastric cancer
.
Data show that, as of now, a total of 14 ADC drugs have been approved for marketing worldwide
.
In recent years, many domestic pharmaceutical companies are also competing to enter the ADC track, including traditional old-brand pharmaceutical companies, such as Hengrui Pharmaceuticals, Kelun Pharmaceuticals, Qilu Pharmaceuticals, CSPC, etc.
; Biotech, such as BeiGene, Junshi Biology, Genting Xinyao, etc.
, the ADC drug market has entered the stage of competition
.
